6% of heavy cannabis users experience severe vomiting condition

Cannabinoid hyperemesis syndrome (CHS) is an emerging medical condition affecting cannabis users, characterized by intense nausea, abdominal pain, and cyclical vomiting that develops after heavy, chronic cannabis use. This first large-scale U.S. study examined 10,255 cannabis users and found that approximately 6% reported experiencing CHS in the past year—a significant prevalence that underscores the importance of awareness among both users and healthcare providers. The research reveals that CHS is not randomly distributed across the cannabis-using population; certain demographic and behavioral factors substantially increase risk.

Several distinct risk profiles emerged from the analysis. Younger males, Hispanic individuals, and those identifying as two or more races showed higher CHS prevalence. Usage patterns mattered significantly—participants who frequently consumed cannabis edibles and concentrates, used cannabis at older ages of initiation, or engaged in riskier consumption patterns experienced higher rates. Additionally, those using cannabis to manage headaches, migraines, or nausea/vomiting reported elevated CHS risk, as did individuals with underlying mental health conditions like bipolar disorder or psychosis/dissociative identity disorder. Interestingly, cannabis use for appetite stimulation and depression management were associated with lower CHS risk.

These findings have important implications for public health policy and clinical practice. The research suggests that cannabis legalization status itself did not predict CHS risk, but rather individual characteristics and usage patterns are critical. Healthcare providers should screen heavy cannabis users—particularly vulnerable populations—for CHS symptoms, while cannabis users themselves should understand that chronic heavy use of potent products carries real health risks beyond commonly discussed side effects. The authors emphasize the need for ongoing surveillance, standardized clinical definitions, and further research into the biological mechanisms underlying CHS to better protect users and inform clinical interventions.